<DOC>
	<DOCNO>NCT02305095</DOCNO>
	<brief_summary>The response therapy fix dose combination isosorbide dinitrate hydralazine ( FDC I/H ) enhance African Americans heart failure reduce ejection fraction ( HFrEF ) compare similar white cohort . This study seek confirm previous genetic sub-study AHeFT suggest functional polymorphism guanine nucleotide bind protein beta polypeptide 3 subunit ( GNB3 ) , C825T exon 10 , influence therapeutic efficacy FDC I/H . This study initiate treatment FDC I/H 500 self designate African American subject systolic heart failure . They follow two year therapy . Clinical outcome ( survival , heart failure hospitalization , change quality life ) FDC I/H compare GNB3 genotype subset . The hypothesis confirm subject homozygous T allele ( GNB3 TT genotype present approximately 50 % black subject ) demonstrate enhance therapeutic benefit FDC I/H .</brief_summary>
	<brief_title>Genomic Response Analysis Heart Failure Therapy African Americans</brief_title>
	<detailed_description>The response therapy fix dose combination isosorbide dinitrate hydralazine ( FDC I/H ) enhance African Americans heart failure reduce ejection fraction ( HFrEF ) compare similar white cohort . Despite clear survival benefit treatment FDC I/H African American Heart Failure Trial ( AHeFT ) , drug prescribe 25 % black subject would potentially benefit . In term enhance response evident A-HeFT investigation , race likely marker difference genomic background . Genetic variation G protein beta sub unit GNB3 study extensively role hypertension . A polymorphism exist position 825 ( T/C ) functionally silent tightly link splicing variant result truncate protein . The GNB3 T haplotype far prevalent black associate low renin hypertension . Evaluation 350 subject genetic sub-study AHeFT suggest GNB3 TT genotype , find 50 % African Americans 10-15 % white , link enhanced therapeutic response FDC I/H . This investigation evaluate hypothesis GNB3 TT genotype marker enhance therapeutic response FDC I/H African Americans HFrEF . The study enroll cohort 500 African Americans HFrEF , initiate therapy FDC I/H follow two year . Subjects genotyped entry GNB3 polymorphism response therapy compare genotype . Therapeutic response quantify use composite score , primary endpoint AHeFT , incorporate mortality , heart failure hospitalization , change quality life ( QoL ) score six month . Aim 2 similar analysis response therapy GNB3 genotype use improvement leave ventricular end diastolic diameter ( LVEDD ) leave ventricular ejection fraction ( LVEF ) echocardiogram six month therapy outcomes measure . Aim 3 use admixture analysis determine first global ancestry ( % African ancestral DNA individual ) impact outcome measure drug response , global ancestry act modifier effect GNB3 .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<criteria>1 . 18 year old 2 . History heart failure LVEF ( less OR equal ) &lt; 0.35 least 6 month OR LVEF &lt; 0.45 leave ventricular internal end diastole ( define diameter 2.9 cm per square meter body surface area OR 6.5 cm basis echocardiography ) . ** Echo must do within 6 month enrollment** 3 . New York Heart Association ( NYHA ) Class IIIV 4 . Background heart failure therapy include angiotensin convert enzyme inhibitor ( ACEi ) angiotensin receptor blocker ( ARBs ) , beta blocker ( BBs ) least 3 month ( documentation intolerance ACEi/ARBs BBs ) 5 . Selfdesignated race African American black ( would include subject whose country origin outside USA Africa , Caribbean , Central America ) . 1 . History intolerance either nitrate hydralazine 2 . Treatment combination hydralazine nitrate previous 3 month 3 . Revascularization myocardial infarction within last 90 day 4 . Received cardiac resynchronization therapy ( CRT ) AND assessment cardiac function document LVEF &lt; 35 % ( le OR equal 35 % ) least 90 day post CRT 5 . Presence clinically significant valvular heart disease , hypertrophic restrictive cardiomyopathy , active myocarditis , uncontrolled hypertension . ( Note uncontrolled hypertension define blood pressure consistenly great 160 mmHg systolic 95 mmHg diastolic ) 6 . Women currently pregnant , plan become pregnant next two year , agree prevent pregnancy . 7 . Subjects continuous home inotropes , leave ventricular assist device , post cardiac transplant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>